Use of hepatitis B vaccine for the treatment of chronic hepatitis B

Hepatology Research

Volumn 37, Issue SUPPL. 3, 2007, Pages

  Ishikawa, Tetsuya ^a,b   Kakumu, Shinichi ^a,b  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Tokai Society for the Study of Chronic Hepatitis B   (Japan)

Author keywords

Breakthrough hepatitis; Combination therapy; HB vaccine; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 35348876015     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00231.x     Document Type: Conference Paper

References (18)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
2. Hoofnagle JH, Lau D. New therapies for chronic hepatitis B. J Viral Hepat 1997; 4: 41-50.
3. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56.
4. Lai CL, Chein RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Therapy Group. N Engl J Med 1998; 339: 61-8.
5. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 34: 1256-63.
6. Boni C, Bertoletti A, Penna A et al. Lamivudine can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-75.
7. Boni C, Penna A, Ogg GS et al. Lamivudine treatment can overcome cytotoxic T cell hyporesponsiveness in chronic hepatitis B: New perspecitives for immune therapy. Hepatology 2001; 33: 963-71.
8. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.
9. Niesters HG, Honkoop P, Haagsma EB et al. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 28: 319-A.
10. Honkoop P, Nesters HG, de Man RA et al. Lamivudine resistance in immunocompetent chronic heaptitis B. Incidence and patterns. J Hepatol 1997; 27: 628-33.
11. Song BC, Suh DJ, Lee HC et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
12. Chien RN, Yeh CT, Tsai SL et al. Determinats for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-73.
13. Ito K, Tanaka Y, Orito E et al. Predicting relapse after cessation of lamivudine monotherapy for chronic hepatitis B virus infection. Clin Infect Dis 2004; 38: 490-5.
14. Couillin I, Pol S, Mancini M et al. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999; 180: 15-26.
15. Akbar SMF, Abe M, Masumoto T et al. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: Vaccine-induced activation of antigen presenting dendritic cells. J Hepatol 1999; 30: 755-64.
16. Michel ML, Pol S, Brechot C, Tiollais P. Immunotherapy of chronic hepatitis B by anti HBV vaccine: From present to future. Vaccine 2001; 19: 2395-9.
17. Shimizu Y, Guidotti LG, Fowler P et al. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998; 161: 4520-9.
18. Akbar SMF, Furukawa S, Onji M et al. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteer. Hepatol Res 2004; 29: 136-41.